Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Tuesday, October 24, 2017 11:43:25 AM
- Owns patented Invisicare® polymer delivery system, prescription and over-the-counter skincare products formulated with Invisicare
- Business model to grow globally by out-licensing its proprietary and patented product line
- Developed multiple cannabis-based products with CBD from imported hemp (non-psychoactive), and will continue to develop line utilizing CBD and THC from marijuana
Skinvisible, Inc. (OTCQB: SKVI) is targeting a global skincare market projected to reach $135 billion by 2021 (http://nnw.fm/61ruV). SKVI also sees a worldwide dermatology market now of $80 billion plus a $30 billion worldwide over-the-counter (OTC) market (http://nnw.fm/0NaOC). It has already completed on the development of 40 products, received numerous technology and product patents, and is now ready to monetize its investment. In the US alone, skincare is projected to reach $10.7 billion by 2018 and the global skincare market is seen growing at a compound annual growth rate (CAGR) of 3.8% from 2016-2021 according to MarketResearch.com (http://nnw.fm/3Uy9z).
It seeks to maximize profits on already-licensed products and grow by adding more licenses to established manufacturers and marketers. Skinvisible has recently formed commercial subsidiaries, Kintari International Inc., along with Kintari USA Inc. and Kintari Canada, Inc. It formed the subsidiaries to bring its cosmeceutical and select OTC products to market.
Skinvisible is a Nevada-based R&D company focused on the licensing of its topical formulations made with its proprietary polymer-based delivery technology Invisicare®. Invisicare is a technology with 14 international patents and is designed to improve the delivery of the active ingredients. Invisicare holds active ingredients on the skin for extended time periods and control their release.
Along with dermatology, the company has also seen a growing demand for topically-delivered cannabis. This is evidenced by its recent announcement with Canopy Growth Corporation in Canada.
The Company in a recent 10Q SEC filing (http://nnw.fm/76cxG) indicated it will continue to out-license its patented prescription and OTC products formulated with Invisicare. Its business model is to increase the value of its product pipeline, boost licensing revenues, capitalize on the success of current licensees, and generate revenue from online and retail sales of its cosmeceutical/OTC line.
The filing added that Skinvisible has named David St. James to the board of directors. An inventor and businessman based in Las Vegas, he is deemed qualified in recognition of his technical abilities and management skills.
For more information, visit the company’s website at www.Skinvisible.com
Recent SKVI News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 05:05:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:11:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM